<SEC-DOCUMENT>0001628280-23-031405.txt : 20230905
<SEC-HEADER>0001628280-23-031405.hdr.sgml : 20230905
<ACCEPTANCE-DATETIME>20230905170046
ACCESSION NUMBER:		0001628280-23-031405
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230905
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20230905
DATE AS OF CHANGE:		20230905

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			X4 Pharmaceuticals, Inc
		CENTRAL INDEX KEY:			0001501697
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				273181608
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38295
		FILM NUMBER:		231236683

	BUSINESS ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134
		BUSINESS PHONE:		857-529-8300

	MAIL ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsanis, Inc.
		DATE OF NAME CHANGE:	20100920
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>xfor-20230905.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:985385aa-7e1e-454b-a800-9291f5721a92,g:b358fd69-ae85-495d-9647-06b31741f173,d:ded6143976c747a9818cb4321dbdd632--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>xfor-20230905</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001501697</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="xfor-20230905.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-05</xbrli:startDate><xbrli:endDate>2023-09-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ided6143976c747a9818cb4321dbdd632_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.844%"><tr><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.068%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.172%"><tr><td style="width:1.0%"></td><td style="width:48.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.617%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%">FORM  </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></td></tr><tr style="height:8pt"><td colspan="6" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">September 5, 2023</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.603%"><tr><td style="width:1.0%"></td><td style="width:22.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.600%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">X4 PHARMACEUTICALS, INC.</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.793%"><tr><td style="width:1.0%"></td><td style="width:32.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38295</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">27-3181608</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.373%"><tr><td style="width:1.0%"></td><td style="width:20.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">61 North Beacon Street,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">4th Floor</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Boston,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Massachusetts</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">02134</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">857</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">529-8300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_______________________________________________________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule  13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.252%"><tr><td style="width:1.0%"></td><td style="width:34.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">XFOR</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#167;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#167;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">240.12b-2 of this chapter).          </span></div><div style="padding-left:360pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Emerging growth company&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ided6143976c747a9818cb4321dbdd632_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 8.01&#160;&#160;&#160;&#160;Other Events</span></div><div><span><br/></span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On September 5, 2023, X4 Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release announcing the submission of its New Drug Application to the U.S. Food and Drug Administration for its product candidate mavorixafor, as an once-daily, oral treatment for individuals aged 12 and older with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item 9.01</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Financial Statements and Exhibits.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="a991pressreleasedatedsepte.htm">Press Release, dated September 5, 2023.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ided6143976c747a9818cb4321dbdd632_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div style="padding-left:252pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  September 5, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Adam Mostafa</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam Mostafa</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a991pressreleasedatedsepte.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ifba1b7e542314067a51487ed48f2cc57_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div><font><br></font></div><div id="ifba1b7e542314067a51487ed48f2cc57_40"></div><div style="margin-top:12pt"><img alt="imagea.jpg" src="imagea.jpg" style="height:88px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:130%">Submission supported by positive results from global, pivotal 4WHIM Phase 3 clinical trial</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BOSTON, September 5, 2023 &#8211; </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">X4 Pharmaceuticals</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Nasdaq&#58; XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for the approval of once-daily, oral mavorixafor to treat individuals aged 12 and older with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, primary immunodeficiency.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;The submission of our first NDA is a significant milestone in X4's journey to transform the care of those living with rare immunodeficiencies,&#8221; said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. &#8220;We&#8217;re excited that this submission moves us one step closer to introducing what could be the first approved product in the U.S. for those with WHIM syndrome. We also continue to advance our clinical program evaluating mavorixafor in people with chronic neutropenic disorders.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The FDA takes 60 days to determine whether an NDA is sufficiently complete prior to accepting it for filing. X4 has requested priority review for the application which, if granted, would provide a target FDA review period of six months from the application acceptance for filing date.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The NDA submission is supported by the results of the global, pivotal, 4WHIM Phase 3 clinical trial of once-daily, oral mavorixafor in individuals with WHIM syndrome. The 4WHIM trial met its primary endpoint and key secondary endpoint and was generally well tolerated in the trial, with no treatment-related serious adverse events reported and no discontinuations for safety events. The 4WHIM data also revealed that mavorixafor treatment resulted in reductions in the rate, severity, and duration of infections in trial participants versus placebo. These and additional 4WHIM Phase 3 data were published in oral presentations at the annual meetings of both the Clinical Immunology Society (CIS) and European Hematology Association (EHA).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">About Mavorixafor and WHIM Syndrome</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHIM syndrome is a rare, inherited, combined immunodeficiency disease caused by reduced mobilization and trafficking of white blood cells from the bone marrow due to over-signaling of the CXCR4&#47;CXCL12 pathway. WHIM syndrome is named for its four common clinical findings&#58; Warts, Hypogammaglobulinemia, Infections, and Myelokathexis, although not all patients experience all symptoms, and not all symptoms are required for a diagnosis. People with WHIM syndrome characteristically have very low blood levels of neutrophils (neutropenia) and lymphocytes (lymphopenia), and as a result, experience frequent, recurrent infections with a high risk of lung disease, refractory warts from underlying human papillomavirus (HPV) infection, limited antibody production due to low levels of immunoglobulin, and an increased risk of developing certain types of cancer. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mavorixafor is an investigational small-molecule antagonist of CXCR4 being developed as a once-daily oral therapy for WHIM syndrome. For the WHIM syndrome indication, mavorixafor has been granted Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Designation in the U.S., and Orphan Drug Status in both the U.S. and European Union. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">About the 4WHIM Phase 3 Clinical Trial</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The 4WHIM Phase 3 clinical trial was a global, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of oral, once-daily mavorixafor in people with genetically confirmed WHIM syndrome. The trial enrolled 31 participants aged 12 and older who received either mavorixafor (n&#61;14) or placebo (n&#61;17) orally once daily for 52 weeks. An open-label extension phase of the clinical trial is ongoing (NCT03995108).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">About X4 Pharmaceuticals </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company driven to improve the lives of people with rare diseases of the immune system. Our lead clinical candidate is mavorixafor, a small molecule antagonist of chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy across a variety of immunodeficiencies, including WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome and certain chronic neutropenic disorders. Following successful completion of a global, pivotal, Phase 3 clinical trial, we are seeking U.S. approval of oral, once-daily mavorixafor for the treatment of people aged 12 years and older with WHIM syndrome. We are also currently planning a Phase 3 clinical program evaluating mavorixafor in certain chronic neutropenic disorders. We continue to leverage our insights into CXCR4 and immune system biology at our corporate headquarters in Boston, Massachusetts and at our research center of excellence in Vienna, Austria. For more information, please visit our website at </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">www.x4pharma.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; or other similar terms or expressions that concern X4's expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, statements regarding the FDA&#8217;s review of the NDA for mavorixafor in WHIM syndrome, if accepted, and commercial launch of mavorixafor, if approved</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any forward-looking statements in this press release are based on management's current expectations and beliefs. Actual events or results may differ materially from those expressed or implied by any forward-looking statements contained herein, including, without limitation, the risk that the FDA does not accept the NDA submission for mavorixafor for the treatment of WHIM syndrome&#59; the risk that such NDA is not approved by the FDA or such approval is delayed&#59; the risk that commercial launch of mavorixafor in WHIM syndrome, if approved, is delayed&#59; the risk that the potential market performance for mavorixafor, if approved, may differ materially from projections&#59; and other risks and uncertainties, including those described in the section entitled &#8220;Risk Factors&#8221; in X4&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 4, 2023, and in other filings X4 makes with the SEC from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contacts&#58;</font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Daniel Ferry (investors)</font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Managing Director, LifeSci Advisors</font></div><div><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">daniel&#64;lifesciadvisors.com</font><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(617) 430-7576</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Brett Whelan (media)</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LifeSci Communications</font></div><div><font style="background-color:#ffffff;color:#0563c1;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">bwhelan&#64;lifescicomms.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>xfor-20230905.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:985385aa-7e1e-454b-a800-9291f5721a92,g:b358fd69-ae85-495d-9647-06b31741f173-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xfor="http://www.x4pharma.com/20230905" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.x4pharma.com/20230905">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20230905_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20230905_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.x4pharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>xfor-20230905_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:985385aa-7e1e-454b-a800-9291f5721a92,g:b358fd69-ae85-495d-9647-06b31741f173-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_fece4bd8-3bce-46d3-84e7-00457823bd6f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_852bf29a-7bd2-4c08-af31-35c25eb9aaa7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a6969689-10a6-40ea-9c66-878d2570b613_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8f1d4b98-164d-4a29-9ea7-c4bba760f2db_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1669f082-2a3d-438d-89c6-f718a7493f9a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_30316318-c9f4-4cdf-90d7-9ca13aa171ed_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_a9c563be-17ab-4ebc-b945-79e050bc4e1f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_3e7250e1-190d-4e7c-ac31-35b650f69c6b_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d2501f20-d544-4ab4-b52b-855cd20d2bef_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_868413a0-ef22-4950-9302-e3365771ef08_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1a5046a7-97db-4e8d-9f92-0b9b6f9efe98_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_893a2bcc-5bbd-4c00-9d27-dd43bb4f9a1c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_35e00fe6-50bb-4c55-9916-11b9a64f3477_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b850d039-8cf6-4545-9c9e-2cfbf50d37f0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e81834df-ee8a-4b92-976f-66f9a43a867c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_556872b8-d59e-4d4d-ac9e-b0453ec5587f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_1b38e718-d4f1-4e4d-a307-1c0e125b7ecd_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d9581004-6cad-4e38-abce-40292599527f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_602b2d91-68c1-44c9-b88a-9583f723ab0e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_490694f8-9d78-4462-80ea-b84e8be881fa_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_52ecdfdc-3268-4d9b-859d-c116b79d14b0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e6c56666-dd11-4d84-ba5f-63728eb99a04_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_db86d47b-dcc5-4f1c-9997-6b68c1be02fc_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_5e8cbfca-ab29-49ac-b026-30e5dc44dbb6_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>xfor-20230905_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:985385aa-7e1e-454b-a800-9291f5721a92,g:b358fd69-ae85-495d-9647-06b31741f173-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.x4pharma.com/role/Cover" xlink:type="simple" xlink:href="xfor-20230905.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f6f15d4d-a88c-450e-a3b5-83c2200d39d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_DocumentType_f6f15d4d-a88c-450e-a3b5-83c2200d39d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b716421e-07e0-43af-86da-eca1adbc6680" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_DocumentPeriodEndDate_b716421e-07e0-43af-86da-eca1adbc6680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ce679e6a-eaf7-4d42-b9ce-9daa7c70d14b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityRegistrantName_ce679e6a-eaf7-4d42-b9ce-9daa7c70d14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7f9eba3a-7516-439b-9b8d-8be59ee262f3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7f9eba3a-7516-439b-9b8d-8be59ee262f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_54af53c7-79fb-4ded-a0f3-8b4ce502a082" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityFileNumber_54af53c7-79fb-4ded-a0f3-8b4ce502a082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d75ddbe8-65a0-4dff-bef3-8d5e81adf538" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityTaxIdentificationNumber_d75ddbe8-65a0-4dff-bef3-8d5e81adf538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9f2d1654-1746-45b6-bfb3-528ae9a36a10" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityAddressAddressLine1_9f2d1654-1746-45b6-bfb3-528ae9a36a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_69e4c1e0-9320-4d2a-8508-a7f04f69b2cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityAddressAddressLine2_69e4c1e0-9320-4d2a-8508-a7f04f69b2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f7d46271-7353-40f6-8323-53d935df3163" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityAddressCityOrTown_f7d46271-7353-40f6-8323-53d935df3163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0ed45edb-ab39-4dff-ac6f-13f7b6218ecd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityAddressStateOrProvince_0ed45edb-ab39-4dff-ac6f-13f7b6218ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b3591492-5a05-407c-91fd-cb9831b8ead9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityAddressPostalZipCode_b3591492-5a05-407c-91fd-cb9831b8ead9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8af7e229-c915-4cae-91f5-ad6bccc11a52" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_CityAreaCode_8af7e229-c915-4cae-91f5-ad6bccc11a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1f7b4f56-7b89-4aeb-9a5e-4ac3e25d8f2d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_LocalPhoneNumber_1f7b4f56-7b89-4aeb-9a5e-4ac3e25d8f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_b5837db8-74d0-4bee-bcc1-f8dbd39bc145" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_WrittenCommunications_b5837db8-74d0-4bee-bcc1-f8dbd39bc145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_acd34dbd-1bc6-4586-911d-1f0c52fb66fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_SolicitingMaterial_acd34dbd-1bc6-4586-911d-1f0c52fb66fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_f908d318-4e82-423e-81ce-39b0ce6500ca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_PreCommencementTenderOffer_f908d318-4e82-423e-81ce-39b0ce6500ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_e27fd491-d970-469c-b153-15b2e1cc5e70" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_e27fd491-d970-469c-b153-15b2e1cc5e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4a65c384-9d72-44fd-80b6-988009c787c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_Security12bTitle_4a65c384-9d72-44fd-80b6-988009c787c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_abea94c0-599b-435d-824b-1c409a42fa14" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_TradingSymbol_abea94c0-599b-435d-824b-1c409a42fa14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a94b1d73-ab4d-460d-bece-ba686c4c6c74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_SecurityExchangeName_a94b1d73-ab4d-460d-bece-ba686c4c6c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8606f15b-863f-4baa-b895-811f11ac81f4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityEmergingGrowthCompany_8606f15b-863f-4baa-b895-811f11ac81f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_d2782539-5e29-4fab-b4fa-92092bce2b2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityExTransitionPeriod_d2782539-5e29-4fab-b4fa-92092bce2b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_179c1d36-84ef-446d-9684-99c8c3f2d83a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityCentralIndexKey_179c1d36-84ef-446d-9684-99c8c3f2d83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c2190c63-0df5-4949-96ba-7af2a368def0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_AmendmentFlag_c2190c63-0df5-4949-96ba-7af2a368def0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>imagea.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imagea.jpg
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M,F@;NO%RU< #TE>K"'O8M'2E]1!HNY7CPDBV,A:X9K2G2%0HPF 4R7 4^5:
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M!&)859Z#X^_Z@PB!A"$YM7X.*(#EUV 9 8ZL=I\1UFO<--LF3=+F$ X*E;M
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MO@*B BG"@SH!GD>9MY=7VN05:QV\\9"$V@@*W[:>?4?XBJC\BHE>?LS3-H@
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MBT8=[VB F8ZG#JAVY[PRW)YO?,UV4*_J@9/VI QP1/^)@:O*';B %3^*9T*
M6'G\%V&U  ""7;.WV5X<-]4=>4#G %*C?7ARH2@0D/_FD_& B>D6MSY810D)
MR^/"PN(T6%'?*GNX9J+UGKK8>O!Q$2F5[^QVUI"<QV]Z)67&UVH2T/O/1&&1
M=8S55CTH@U^8]/>T!/RN MEC(T;9O U;G&]_>*"1PH,L-0I(9H(=M1<X8YG=
MDU1['1$B[AV[=+7U5'G>7M7'STZ%LMM'_O !X.H^_[XPI.#N;HU.L]9L=*/@
M)J.=0,@ 1_2?&KA!4A&*3"R15.QX=K]0.ZAWG2Q/K[&O6R%*]"$::\M+?:PO
M#8OB/X\*<+&"6%<%*_[))1>BA(F59*B71>VB<NX;VFC3-^^P=:KKN8;7K'/O
MX>'/#B:HX,<"4;; 2 0NBQH^,1TCA._!'\#0-=3#J]\Y@Z0(6<:BO@IZZB?8
M-A:HT%9&%?GIF90!+NX H,4.J^T>TL<E\]=OM4<JU<GDBZ)\__J,=]( P=&)
M<]E$)*^MW"#<*(*BKGU'6,VL12Y7_Z:9Y(_A$$->[_NE#'!$_VF!2X(!+%"J
M2$#L5@ KY3_5&;_FW;!DA7673Y;KED>-=N=?H-50B#*9Y(ZH58+ CQ- ^45*
MA,8:59_&$LC<1RROL\+>@VS(S 4>^%#^]-4;[:X!==:YK%8 1/ $=1IF51?W
M^;V U!44((J9!JQY #J "XA5?WFCW:9Z^-IA_*:PVL=3/P2.S.FLA]P)<@
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MU)]*>]U['4<0,]$;T[EDL#U:UV"K6YI5 _T$*RM_6@=,8YT8V"JI8-I&9R0
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<>S)]!)/9_P*,L^VN-*5Z>P    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140168179809376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  05,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">X4 PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3181608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">61 North Beacon Street,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">529-8300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XFOR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>xfor-20230905_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="xfor-20230905.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2023-09-05</startDate>
            <endDate>2023-09-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001501697</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-09-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">X4 PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38295</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">27-3181608</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">61 North Beacon Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Boston,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">02134</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">529-8300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">XFOR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !:()5<'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  6B"57V7!=ON\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M3L,P#(=?!>7>.FT'$E&7"]-.("$Q"<0M2KPMHOFCQ*C=V].6K1."!^ 8^Y?/
MGR6W.@H=$CZG$#&1Q7PSN,YGH>.:'8FB ,CZB$[E<DSXL;D/R2D:G^D 4>D/
M=4"H.;\#AZ2,(@43L(@+D<G6:*$3*@KIC#=ZP<?/U,TPHP$[=.@I0U56P.0T
M,9Z&KH4K8((1)I>_"V@6XES]$SMW@)V30[9+JN_[LF_FW+A#!6]/CR_SNH7U
MF937./[*5M IXII=)K\V#YO=ELF:UTW![PM^NZLKP;E8K=XGUQ]^5V$7C-W;
M?VQ\$90M_+H+^0502P,$%     @ %H@E5YE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M"  6B"57H,MR,&0$   E$0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;)V8:W/B-A2&_XK&[73:&1)?N(2DP(Q#2)?97&A@NSOM](.P!6C6EEQ)#N'?
M]\@0FW;-,>T7;-D^+X]TI/=8'FRE^JHWC!GREB9"#YV-,=F-Z^IHPU*J+V7&
M!-Q92952 TVU=G6F&(V+H#1Q \_KN2GEPAD-BFLS-1K(W"1<L)DB.D]3JG:W
M+)';H>,[[Q=>^'IC[ 5W-,CHFLV9^93-%+3<4B7F*1.:2T$46PV=T+^Y#;HV
MH'CB-\ZV^NB<V*XLI?QJ&]-XZ'B6B"4L,E:"PN&5C5F26"7@^.L@ZI3_:0./
MS]_5[XO.0V>65+.Q3#[SV&R&3M\A,5O1/#$O<ON!'3I4 $8RT<4OV>Z?[70<
M$N7:R/00# 0I%_LC?3L,Q'& ?R(@. 0$!??^CPK*.VKH:*#DEBC[-*C9DZ*K
M133 <6&S,C<*[G*(,Z.Q?&5JX!J0LA?<Z!!VNP\+3H3-679)O&Z+!%[0_F>X
M"P0E1E!B!(5>&\,@?X1+;10DZL\ZHKU"IU[!SMX;G=&(#1V8GIJI5^:,?OC.
M[WD_(WSMDJ^-J8_N9)3#7#1DL<M8'1P>WK_XB$!T2HC.>1 SIKB,R43$!))>
MRX,K%>DK\M>4P&[)UD45)\)PLR,O;,UM"@'RB::U9+C.EPZ9?0A?'L/QY--B
M.@X?YBTR?1I?(HB]$K%W#N)41%)E4E'K"BTR-S""1"HREKDP:@?'N)8;%[^;
M((17)>'5.83W/&'D*4^7]2L3U_ \_Z+=#ZZ["$^_Y.F?P[.@;V0:P\3C*QX5
MPX;0X8K!U47;[\.B["-XUR7>]3EX81S#@M>M]Q/R ,^19U&;15RQYY,GJ<R&
MW#(:03?A'AAK"V'UO<IHO?]/N]C*6A/&)3M >I](J3# HTK@_R? L6W!PEC(
MK:B%P^5N)10O@8Y=51U\U-R_02L7[4S)5RZBVE0W:#Z&&%I5&'S<VO^--H-N
MTX3\SK.33M*@Z 5^NX.Q5?7"QVV^R& (+VNG47"!?O<* ZF*@X^[^H.,8$QF
M&RDP8VL0Z0;7%_VVYV%$52WP<;_^K+@Q3,# I&DN#K:F:ZEPH15--,.0*O/W
M<>>>RX1'W'"Q)H\PO16G22T/KM+(4YF_CWOU3+&+"(:'P?K:O_LP$<-;VO-J
M=2)_N%XC6>7[/F[3WY!-M<Z!K!$0EVT"#"JO#W!C7G #)5RNB!_\N/R)S%F4
MPWS;U;[5XDIV?A:%2$9?6R2CBKS2)&?D>^\2*CW)H+MZ0Q6*756  +?LA:*Q
MG7[S7;J4M9.O0>#+_?,+1G*T'<#-^7W$R.0MVE"Q9B=?)QN$GL+Y7?@KQE0Y
M?7"6TT]2IM9VE'X!!2C D*&,BOK<XH*-\ZTR^@#WZ0/:&-:" J.=PC)X(Q]9
M/10NY<&TZGI^[QIS_J!R_@ W[1#69URLT?N$KFMY<(&3@^0>;7KM!X1':M.B
M2<)6(.1=7H&NVN_)]PTCLV(?O)0&=M7%Z891, S[ -Q?26G>&W9K77X9&?T-
M4$L#!!0    ( !:()5>?H!OPL0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7
M;6O;,!#^*T(_8&YB:N*1&+9 8;"-0O-A7Y58=@1Z\62Y<_KKI[-L)VEU9=V'
ML<VAR=T]NKM'=R>9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8Q
MYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*
M%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2
M,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T]
M.PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3), Z)Q17B@%JXUF X?)8Q1\V .7
M\@%:^*VZBMU7)/3B4PEM(+#52?2$1C&$"0K$OXP68E^$O?VML*01C\9][/QN
M]*!_[XSC]Y97HA_TOIKS8]$7>'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D
M'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3
M\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_R
MBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P
M6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8
MLAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z
M'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8
M"<:1/,<0F,7XC&894IT,/O'^8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^
M>Q\ETWLJ.?]74_P$4$L#!!0    ( !:()5>7BKL<P    !,"   +    7W)E
M;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE
M<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;
M8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R
M]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY
M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ %H@E5ZK$(A8S 0  (@(
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    "  6B"5799!YDAD!  #/ P  $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ %H@E5YE<G",0!@
MG"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    "  6B"57H,MR,&0$   E$0  &               @($."   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ %H@E5Y^@&_"Q @
MX@P   T              ( !J P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M"  6B"57EXJ[',     3 @  "P              @ &$#P  7W)E;',O+G)E
M;'-02P$"% ,4    "  6B"57JL0B%C,!   B @  #P              @ %M
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ %H@E5R0>FZ*M    ^ $
M !H              ( !S1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ %H@E5V60>9(9 0  SP,  !,              ( !LA(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="xfor-20230905.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="xfor-20230905.htm">xfor-20230905.htm</File>
    <File>a991pressreleasedatedsepte.htm</File>
    <File>xfor-20230905.xsd</File>
    <File>xfor-20230905_lab.xml</File>
    <File>xfor-20230905_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "xfor-20230905.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "xfor-20230905.htm"
     ]
    },
    "labelLink": {
     "local": [
      "xfor-20230905_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xfor-20230905_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "xfor-20230905.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "xfor",
   "nsuri": "http://www.x4pharma.com/20230905",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230905.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.x4pharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230905.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-23-031405-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-031405-xbrl.zip
M4$L#!!0    ( !:()5<UG#$[E X  *4U   >    83DY,7!R97-S<F5L96%S
M961A=&5D<V5P=&4N:'1MY5MM<]LV$OY^OP*7S*7VC*18CFPG=IH9UXXGF6E>
M:J=-OMU )"BB)@D6 "VKO_Z>78 2]6([O29Q;BZ9B2T2+XO%[K//[BK/<U\6
M+Y[G2J8O_O'\G_V^.#5)4ZK*B\0JZ54J&J>KB?B8*G<I^OTXZL34,ZLGN1>[
M.[M/Q$=C+_65#.^]]H5ZT:[S_''X_/PQ;_)\;-+9B^>IOA(Z_?&!SL9R.#Y0
M>Z/=)\/1SOZ!W!N.GAZH=/0TVTV2O8-_#Q]@*H:'.<[/"O7C@U)7_5S1_H<'
MN[4_FNK4YX?#G9U_/5@:Y]6U[\M"3ZI#EA9O,X.SQ=>)*8P]?+C#?X[H33^3
MI2YFAS]\T*5RXJV:BG-3RNJ'GI.5ZSME=18&.OVG.AS2YOQQ&J7!.H6N5"O=
M<)=$>GF=Z['VXMFSP?#Y8QK?GFE^LB 8U&-?+(_X?$V-=C:J2MH)M.5-S=)B
MB"XG0A8>2Y9RHN3@]WKR0#B;K#P(T^,YGCZMKX_B4F/CO2D/]W#T*V6]3F01
M=<SJ#J_;*QGNU=>;Q*IEFL*N^H7*_.'^X"FMUC[CJVH?=JXP@3DI^^!65:U?
M_-*LS[CY$TP;6WW3C8_NNG$VPD\C\3Z7MI2):EA#3AQ7E6FJ!%9UT8Q+[9PV
ME3 9V]BI;2;BN*X+#/7T?.OMZ?&V\$;\.K@8B+/38Y$9*][(*V/UM:3?=24^
MOGK]1ES,JM2:4OUE5=R7 N<NPRL=:H_AR9)*1ZLJ?4(J[6C--75M+('3>"9J
MX[375TI8Y9K".Y%!'6)2F+$L>J+65P8[B!$K"W?BE'@B$BQ/MR*\U;+X0JK[
MX@JZU<)^>G?QX=W;GKA0M5?E6%FQUPM@_.CAT]WA\$BT FZ2:F__23+\XE(%
M9TU58BR;\6%3I<K2J$T><9M\7TMKMRKE[V^Z9KF\Z=9;Z5+YQZ.'>T^/Q*>S
M=^?;/2%%8LI:5C.16AAO1;ZNR]H:&++/E2CPT!$\U,K4A1)3[7-AI54BU4[!
MBODEC=1EV51*N)F#'?2P3BIG0D:P27F(6P(<>0?DT(Q?*TWN=>%! 9PX,R;%
MDFF<E"+\:N=MG'=&\PB2:**LZ0SP+&QD($ _E5!D3\ B"E%V\(LV(H8!((/O
MZ+0AC$3X2<5PE_<R!6PGG)M]=^NCM-[UQ*M9;2:R1*B"BS>D[5++GGA=92HA
M@3"$IK^9J<)<2LATK=TVU!-@DC1/:@0R6(0[.POZ,ZG*=*)5E<P&-SCVMW7Z
MS99$KKV[<_1A[4Y-8T6FK?,"MR@T-"D<8$OC4!+B003EO(&9(&Q\&OW@Q.^8
M4:E9N 9(A"LI^0(3LC$V+>/8#(G]+:QO15M:N1X+!;QQ4J?BO6P**<[E1%8]
M./S@=( ?0&:=$J>DBSG)M<K$RVN5- S;[S*LA9O&GNL8,1#QR!\5P]K!$610
MUPE;I\]A/C[':3O** TY3@/W(*?PJ@;8XR1L<+KRUJ1-PD>BR8EI"@21X')!
M?\& L7K-0\D^@T=0( Y63HI9V&5K60/Q$>9?.(-5*Z^K1M&6,KV2< .^H'G4
MP=(3*TNAX"@-O CBE,NAO>OU26X-YHD*2K&F5O0[0,!8^(<;M-K_CJV6S)4H
MC)>7N)K]'0&$<J2<5"&F DQPT%Q!R18&TAJP:[)@8[Z8,586&$Q.&[!#)@D"
M'VD.O)J4EFEL/!F0#2'(@PS\T<#D^1XQ1?L9'EUI %\'J>;8-\UUDO>$S@3N
M!8$^[8DIFP;9 DP7[N1!?I7G<\2%:F@#N B[=?H:=E?Y/)*/U>6#L&P'"U&A
M!:^^9["A:Z/+Z#@7WTN'>]%!6]H5P]$*\>K=RKSNC!)PA6Y\V.1U)&;8(RQ9
MXI8TY&GQ755I;70$GTM G@,_J=*U5U-8S415"B+ XJ:J@(RFP$<Z:P0!WJ$7
MQ*AB *,DMV]5P>-(U0;@ [>'<P*J$-H]66/4&6V$B7#?"!)L(([-PLE,P4S#
ME.ZY8"@R( LL3\FBA;ZE<-J*$N\CR&P501CO$$] Q^E!3(@'GPBA,FUB*,=M
MZ'D8Y1FLT5I2EJ?!5G 4.A<.6!< Z;%A,7%.6H:R-YJYQK99_JD"<M?-N- N
M#\+Q9=<0%U)'-3">TVI0#-VD(@]GTT)6F?.[D]: 7G,D*LQD)BX,@ *JVSIY
M?;'-LKQL""F!)J]4*7T8=>P<QD72\O+5\?;WX7R;B>KQV#1^*>&C8]V>\7U;
M>%ARPT Y K'254[&12 *W!YC8KI&LEH6"[K1N( E;*OXM31CX..?$3EQ:/ 3
M"@67A)FP!& U L&X($Z:P$L[F#NFF ^GMV8*H^;XBU!N^T2%9!'GLQ%].CD?
M/7HX.CC";S^#<-8@BE,Y&XBU4U6RA%",191;<APW)=!^ 649013L-!#\OT%3
M>U27R4TS(70!*A7D>UXSA*AKBC>*8@@]=[.R]J:,J[2CVZ>"J!J%0&VC\!(:
MEY,*N3*@Y7V'72P?. ']D@FB,O@]G0U(F$N0-&AQ)@JH->B] 'X4[)>1E.0:
M'[<6#$4&-RP@3VZ2&2416^%#>!O$EFPTC%>][@$SCMX5'EJP1&L)UCK Q')+
MD<,8!02])#F*AB)J,"J:EM$Q#(2>TG4$$PG9Z(SL(&]*@$,M:UT4!CBJ+3!M
MZ]7[W[87&_7 ?DL=4-MKJENVG) L,]H7Z62AC6#F[8W'0U((HV(JV7DK;DI3
M3$VB@/MZ25@[JT-2EQ!1L(-U1K=2D^/*9ZA^(-7F" 0^?6,M-);M=A93Y-B9
MHO'K4VZ$P>Z_N5W4\B:J/\8)+_LR@^T<R@*^Y![\I9+M'7M^5\QHJ0[GP@TC
MZ_!Z(F, ="5\IU^"/R1-00'-RXFAI)DNF-$'60>3P& (*CK#@@R%\$BD6-8S
M=N$5WG,6>>P*8@&* NOL+?$#XL1CI:J6X(J?Z+X\4@M"FP]QFU/%4!FFGTF(
M^P%^=+G\G(SZG #FO0*F@"(DW??=?"F,?6?K'"KBV@$5%!JF%O. SHG54LS^
MM<(Z&^S_>XO.?L[06J8S)R<?-M85OSU_OY5\3]GD6L(.NTA-B?41MU,#H@:?
MQGA\BERO3Y35FJ*@$24P6X>B*,[3 !M3M@'BIJ9-;$->K2AZRV3&EQQ)+O%^
M2[MV#/Z6%)AX>1N/( 4R=0K*&Q*!<#!5!3'%D^$R>=U07\J)52=*4\JO-">A
M74&VJD</]X='P]$V!&XU,7]ZL,W'(&^EN!7.0=/V=D%XU25B[3&(+F)>OY!C
M!<FNO:HXE:KY3B(?6;D83=6+B2%\V'I[\F'GR;-G>\.=I_\#A'5#W^.>O6"#
M1,Q5*5_K.\!R1_MC#2;3'?MUBK0#\0XLLE R76R-H)]JJ@B0=!T#I'HE!Q-Q
M0S!)<E6:2ZJAD!F#_=D87SA%U&YCG*G6O:^--#*QQI&"KJ35T54W%/V(TQ1-
MRJWA+U>=Y7<M(;J][H7X!^HV)0%<DR3*N:PIVD+1O-*]5HW8#(5(Z15S9@>G
MI25#4.K6LF]#J[:DM$C"%S;10LY,2>LV%K:7"XBV+2(&WHN= #I514+)=>GO
MKB1^IC:Q=;=L2936DF]0OJ.!6' H"MMX%:R+#K)DU.0\G&;#ZD*29&MJ RE!
M??\_&I@'-B*)?C)4BNXAN75.)CGR/^^#9N)4*@E(F^0BQA<H4UU3JL?) 5;X
M#598P:J.&T?7%[A0::@\75$A.Q(5J)_4=:7!=WGAJ1H[2AZQS]=MCFV"HMN:
M8]/I=' ]"M@S@ W?1Y?J2P0727^_0G#!_2*/2_L_&\/NR7TI<C1W[QQ+.ZYA
M48TOF!NY$1R.:WHL=!&%=G.AV?DC3R[!>&-E(I:,P;RH1ME89&F(((6<+L$M
M37J/<$2N=;$8]K-NTP]QKKB;<YPP#@U!'GJ,^M@[56E;LNN(4\H9-4&X1Z,S
MO:CM3@$/KFW!8-2\UQ,?39$^KS[CGLK:P$T/7;[I*=4!$K_ZE$!P]1FEY<3L
MO%I] Z#"65>?@H!IX-K:ADC<R@V+X%J12ZU+8LWOFP0TGK0G-^@CP.KJ\]!0
MF#\%@AEFGT[#/B4"BK*EH\=0"!D8ESY\Z%I1@2 V\H*Z9(RMW)55DQF3=GK
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MH[1!.!9O6"YONEW[[R<;: 7[M5[/?@-02P,$%     @ %H@E5\E?SV;X"@
M^F0  !4   !X9F]R+3(P,C,P.3 U7VQA8BYX;6S576MOVS@6_=Y?H<U^V07*
M6J1>9#'-H)MI!\5FVJ!),8-=+ R^E AC2X&L-,F_7U*V$RNF;)&R54T+-*I-
M79Y[I'-Y+\FR/_W\,)]YWV6YR(K\W0E\XY]X,N>%R/+K=R??KCX"?/+SZ:M7
M/_T-@#_^]?7<^Z7@=W.95]Y9*6DEA7>?53=>=2.]WXORS^P[]2YFM$J+<@[
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MXO8'@SYT'%GY%DQ8";S-92<U;QD;3+IM;FSJM+5-SZ3^HEA4=/:?['8YU).
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MTF&WZ-GBM]N2YTMCPRUXMKC16.YL:V,OS_41%5?JUFD4Q3A!# ,1J4PJ%*$
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M1&(\* O -4]B#V#\K1.].)%CYV1_.H\"FW?%$GZY7GFH<R5=4B)D)+/)(_*
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M_S,G!W\"4$L! A0#%     @ %H@E5S6<,3N4#@  I34  !X
M ( !     &$Y.3%P<F5S<W)E;&5A<V5D871E9'-E<'1E+FAT;5!+ 0(4 Q0
M   ( !:()5?^X\>\XP\  ))S   1              "  = .  !X9F]R+3(P
M,C,P.3 U+FAT;5!+ 0(4 Q0    ( !:()5<:>-UY; (  ' '   1
M      "  >(>  !X9F]R+3(P,C,P.3 U+GAS9%!+ 0(4 Q0    ( !:()5?)
M7\]F^ H  /ID   5              "  7TA  !X9F]R+3(P,C,P.3 U7VQA
M8BYX;6Q02P$"% ,4    "  6B"57/]8 9 8'   /-0  %0
M@ &H+   >&9O<BTR,#(S,#DP-5]P<F4N>&UL4$L%!@     %  4 4 $  .$S
$      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
